Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Regeneron (REGN) Gains But Lags Market: What You Should Know
10:00pm, Friday, 24'th Jun 2022 Zacks Investment Research
Regeneron (REGN) closed at $612.49 in the latest trading session, marking a +0.84% move from the prior day.
Regeneron (REGN) Dips More Than Broader Markets: What You Should Know
10:15pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Regeneron (REGN) closed the most recent trading day at $586.84, moving -0.14% from the previous trading session.
Regeneron Pharmaceuticals: Lack Of Appreciation For The Purchase Of Libtayo
06:40am, Tuesday, 21'st Jun 2022
Regeneron acquired the global rights to Libtayo from Sanofi. The deal also brings acceleration of repayments to Sanofi.
Regeneron (REGN) Moves 4.4% Higher: Will This Strength Last?
01:25pm, Monday, 20'th Jun 2022 Zacks Investment Research
Regeneron (REGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength
Regeneron (REGN) Moves 4.4% Higher: Will This Strength Last?
10:53am, Monday, 20'th Jun 2022
Regeneron (REGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength
4 Top Biotech Stocks To Watch Today
03:00pm, Friday, 17'th Jun 2022
As the industry continues to make new discoveries, could biotech stocks be in focus?
Is Regeneron Absurdly Cheap or Has it Become a Value Trap?
10:53am, Thursday, 16'th Jun 2022
The company has made some recent moves that could change its short- and long-term prospects.
Regeneron Pharmaceuticals, Inc.'s (REGN) Management Presents at Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript)
03:22pm, Tuesday, 14'th Jun 2022
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Goldman Sachs 43rd Annual Global Healthcare Conference Transcript June 14, 2022 11:40 AM ET Executives Bob Landry - Chief Financial Officer Marion McCour
Regeneron Looks Significantly Undervalued
10:57am, Thursday, 09'th Jun 2022
As I was browsing through Dodge & Cox's Global Stock Fund annual letter for 2021 (published in February 2022), I came across the asset management company's commentary on Regeneron Pharmaceuticals Inc.
Regeneron Gets Wall Street-Low Price Target. The Stock May Be Done Outperforming the Market.
12:54pm, Monday, 06'th Jun 2022
Jefferies initiates coverage of Regeneron Pharmaceuticals at Underperform, sending the stock lower.
Regeneron (REGN) to Buy Sanofi's Stake in Libtayo, Stock Down
05:18pm, Friday, 03'rd Jun 2022
Regeneron (REGN) will obtain global rights to Libtayo from Sanofi in exchange for an upfront payment of $900 million and royalties.
Regeneron to buy Sanofi's cancer drug in $1B deal
06:36pm, Thursday, 02'nd Jun 2022
Regeneron CEO Leonard Schleifer on the decision to spend $1.1B to buy Sanofi's cancer drug portfolio. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman and Dan Nathan.
Why Regeneron Wasn't a Healthy Stock Today
06:30pm, Thursday, 02'nd Jun 2022
The company is forking over $900 million in an upfront payment to fully own a cancer drug.
Regeneron to pay Sanofi up to $1.1 billion plus royalties for its stake in Libtayo collaboration
07:50am, Thursday, 02'nd Jun 2022
Regeneron Pharmaceuticals Inc. REGN, -0.88% announced Thursday an agreement in which it will pay up to $1.1 billion plus royalties for Sanofi S.A.'s SNY, -0.08% stake in the Regeneron-Sanofi collabora
FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease
12:04pm, Tuesday, 31'st May 2022
The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for review submitted by Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) f
